Esther Conde
A thoracic and molecular pathologist at Hospital Universitario 12 de Octubre in Madrid, Spain, Esther has worked hard to advance molecular and digital technologies within pathology. A pioneer in targeted therapies, she says, “While I was in the middle of my PhD project, the predictive role of EGFR mutations in patients with lung cancer was discovered. I felt very lucky to be one of the first pathologists to implement these assays!” What does she think is pathology’s next leap forward? “The clinical use of artificial intelligence for the assessment of predictive biomarkers in patients with cancer.”
